Abbott Laboratories (NYSE:ABT) – Analysts at Leerink Swann issued their FY2017 earnings estimates for shares of Abbott Laboratories in a research report issued to clients and investors on Thursday. Leerink Swann analyst D. Antalffy anticipates that the healthcare product maker will earn $2.49 per share for the year. Leerink Swann also issued estimates for Abbott Laboratories’ Q4 2017 earnings at $0.72 EPS, Q1 2018 earnings at $0.56 EPS, Q2 2018 earnings at $0.72 EPS, Q3 2018 earnings at $0.77 EPS, Q4 2018 earnings at $0.78 EPS, FY2018 earnings at $2.83 EPS, FY2019 earnings at $3.16 EPS, FY2020 earnings at $3.52 EPS and FY2021 earnings at $3.91 EPS.

Other analysts have also recently issued research reports about the stock. BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a report on Thursday. BidaskClub cut shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a report on Friday, July 21st. Morgan Stanley reaffirmed an “equal weight” rating on shares of Abbott Laboratories in a report on Monday, July 10th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Abbott Laboratories in a report on Thursday, August 17th. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $56.81.

COPYRIGHT VIOLATION NOTICE: “Abbott Laboratories (ABT) Forecasted to Post FY2017 Earnings of $2.49 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/23/abbott-laboratories-abt-forecasted-to-post-fy2017-earnings-of-2-49-per-share.html.

Shares of Abbott Laboratories (ABT) opened at 56.32 on Monday. The stock has a 50 day moving average of $53.27 and a 200 day moving average of $48.51. The stock has a market cap of $97.85 billion, a P/E ratio of 78.88 and a beta of 1.06. Abbott Laboratories has a one year low of $37.38 and a one year high of $56.60.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion for the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 14.50%. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.59 earnings per share.

Institutional investors and hedge funds have recently modified their holdings of the stock. Tributary Capital Management LLC bought a new position in Abbott Laboratories during the third quarter valued at approximately $106,000. Heritage Trust Co raised its position in Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after acquiring an additional 200 shares in the last quarter. Winfield Associates Inc. raised its position in Abbott Laboratories by 3.9% during the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after acquiring an additional 89 shares in the last quarter. Thompson Davis & CO. Inc. raised its position in Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after acquiring an additional 370 shares in the last quarter. Finally, V Wealth Management LLC bought a new position in Abbott Laboratories during the second quarter valued at approximately $127,000. 71.45% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Sharon J. Bracken sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total transaction of $98,320.00. Following the transaction, the insider now owns 28,806 shares of the company’s stock, valued at $1,416,102.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Stephen R. Fussell sold 196,550 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the transaction, the insider now directly owns 221,488 shares in the company, valued at approximately $10,963,656. The disclosure for this sale can be found here. Insiders sold 333,310 shares of company stock valued at $16,857,255 over the last three months. 0.76% of the stock is owned by insiders.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be given a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.88%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is 83.47%.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.